www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 27), pp: 43752-43767 Research Paper Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients Rachid Abaji1,7, Vincent Gagné1, Chang Jiang Xu1, Jean-François Spinella1, Francesco Ceppi1, Caroline Laverdière1,2, Jean-Marie Leclerc1,2, Stephen E. Sallan3,4, Donna Neuberg5, Jeffery L. Kutok6, Lewis B. Silverman3,4, Daniel Sinnett1,2 and Maja Krajinovic1,2,7 1 Research Center, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada 2 Department of Pediatrics, University of Montreal, Montreal, QC, Canada 3 Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA 4 Division of Hematology/Oncology, Children’s Hospital, Boston, MA, USA 5 Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA 6 Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA 7 Department of Pharmacology, University of Montreal, Montreal, QC, Canada Correspondence to: Maja Krajinovic, email:
[email protected] Keywords: acute lymphoblastic leukemia; asparaginase; exome-wide association; pharmacogenetics; whole-exome sequencing Received: April 21, 2017 Accepted: April 27, 2017 Published: May 17, 2017 Copyright: Abaji et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Allergy, pancreatitis and thrombosis are common side-effects of childhood acute lymphoblastic leukemia (ALL) treatment that are associated with the use of asparaginase (ASNase), a key component in most ALL treatment protocols.